Stock 688321 SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.91 CNY +0.55% Intraday chart for Shenzhen Chipscreen Biosciences Co., Ltd. +6.00% -0.18%
Apr. 28 Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection
MT
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug
MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets
MT
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial
MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback announced on July 7, 2021, has expired.
CI
Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for Lung Cancer
MT
Akeso, Inc. Announces Collaboration with Chipscreen Biosciences to Initiated A Clinical Trial of Pd-1/Ctla-4 Bi-Specific Antibody in Combination with Chiauranib for Pd-(L)1 Pretreated Es-Sclc
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688321 Stock
  4. News Shenzhen Chipscreen Biosciences Co., Ltd.
  5. Highlights